Analyst Reco. Sanofi

Stocks

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-10 EDT			5-day change	1st Jan Change
76.23 ^EUR	-0.33%		+0.55%	-7.85%

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT

07-08	AlphaValue/Baader Europe Cuts Sanofi Price Target After Scrapped Late-Stage Rare Neurological Disease Trial	MT
07-07	AlphaValue turns bearish on Sanofi, the stock rises...
07-07	Sanofi: Wounds may take time to heal
07-06	SANOFI : Goldman Sachs is Neutral	ZD
07-06	SANOFI : JP Morgan reiterates its Neutral rating	ZD
07-02	SANOFI : Jefferies keeps its Buy rating	ZD
07-02	Sanofi rebounds, Oddo BHF reiterates its bullish view
06-15	SANOFI : Gets a Buy rating from Deutsche Bank	ZD
06-10	CIC Corp. & Institutional Banking Trims Sanofi PT, Keeps Buy Rating	MT
06-09	SANOFI : Deutsche Bank remains its Buy rating	ZD
06-04	Sanofi among top performers as Jefferies reiterates Buy rating
06-04	SANOFI : Gets a Buy rating from Jefferies	ZD
05-28	SANOFI : Deutsche Bank maintains a Buy rating	ZD
05-08	Berenberg Calls for More Acquisitions from Sanofi; Estimates Updated	MT
05-05	SANOFI : JP Morgan sticks Neutral	ZD
05-04	Morgan Stanley Downgrades Sanofi to Equalweight From Overweight, Adjusts Price Target to $52 From $55	MT
04-28	Sanofi remains flat despite positive outlook from Oddo BHF
04-28	SANOFI : Bernstein reiterates its Buy rating	ZD
04-28	SANOFI : Buy rating from Deutsche Bank	ZD
04-27	Sanofi in the red as UBS maintains Neutral stance
04-27	SANOFI : UBS remains Neutral	ZD
04-24	SANOFI : UBS remains Neutral	ZD
04-24	SANOFI : Gets a Buy rating from Deutsche Bank	ZD
04-23	Sanofi: Quarterly beat is fine, but longer-term growth prospects remain questionable
04-23	SANOFI : Barclays reiterates its Neutral rating	ZD